Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | 15.78% | 15.16% | 23.13% | 28.35% | 19.11% |
| Total Depreciation and Amortization | -9.79% | -8.24% | -1.58% | 3.64% | 4.41% |
| Total Amortization of Deferred Charges | -9.75% | -8.80% | -29.14% | -65.37% | -65.54% |
| Total Other Non-Cash Items | -37.96% | -44.30% | -60.13% | -69.47% | 12.96% |
| Change in Net Operating Assets | 64.78% | 140.63% | 37.67% | 153.17% | -48.75% |
| Cash from Operations | 16.70% | 17.34% | 17.00% | 22.42% | 21.01% |
| Capital Expenditure | 47.12% | 38.57% | 41.55% | 11.86% | -1.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -100.00% |
| Cash from Investing | 47.12% | 38.57% | -100.45% | -100.25% | -100.35% |
| Total Debt Issued | -69.05% | -66.87% | -64.25% | -61.01% | 71.90% |
| Total Debt Repaid | 100.00% | -4,110.33% | -4,223.68% | 60.70% | 60.65% |
| Issuance of Common Stock | -71.82% | 0.44% | 74.22% | -52.39% | -53.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | 35.68% | -0.95% | 15.19% |
| Cash from Financing | -58.23% | -74.46% | -38.41% | -50.82% | 9.52% |
| Foreign Exchange rate Adjustments | -1,237.86% | -337.09% | -141.86% | -151.13% | -118.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -115.40% | -334.25% | -348.73% | -223.48% | -327.18% |
